Treatment Patterns and Recommendations for Improving the Management of Hepatocellular Carcinoma in Saudi Arabia
Ashwaq Alolyan,Kanan Alshammari,Mohammad Arabi,Ahmed Alshehri,Hamad Alsuhaibani,Fahad Ibnshamsah,Abdullah Alsharm,Mervat Mahrous,Adnan Al Zanbagi,Mazen Hassanain,Shouki Bazarbashi
DOI: https://doi.org/10.2147/jhc.s442842
2024-02-17
Journal of Hepatocellular Carcinoma
Abstract:Ashwaq Alolyan, 1 Kanan Alshammari, 1 Mohammad Arabi, 1 Ahmed Alshehri, 2 Hamad Alsuhaibani, 3 Fahad Ibnshamsah, 4 Abdullah Alsharm, 5 Mervat Mahrous, 6, 7 Adnan Al Zanbagi, 8 Mazen Hassanain, 9 Shouki Bazarbashi 10 1 Department of Medical Oncology, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia; 2 Department of Oncology, King Khalid National Guard Hospital Abdulaziz Medical City, Jeddah, Saudi Arabia; 3 Department of Radiology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; 4 Department of Medical Oncology, King Fahad Specialist Hospital, Dammam, Saudi Arabia; 5 Department of Medical Oncology, King Fahad Medical City, Riyadh, Saudi Arabia; 6 Department of Oncology, Prince Sultan Military Medical City Hospital, Riyadh, Saudi Arabia; 7 Department of Medicine, Minia University of Egypt, Faculty of Medicine, Minia, Egypt; 8 Department of Gastroenterology and Hepatology, King Abdullah Medical City, Makkah, Saudi Arabia; 9 Department of Surgery, King Saudi University, Riyadh, Saudi Arabia; 10 Department of Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia Correspondence: Shouki Bazarbashi, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia, Email Hepatocellular carcinoma (HCC) is the sixth most common type of cancer in the world associated with high morbidity and mortality. Despite being a significant healthcare burden there is limited information on the unmet needs and current treatment practices for intermediate and advanced-stage HCC in Saudi Arabia. This article analyzes the gaps and provides expert consensus on the management strategies for unresectable HCC in Saudi Arabia. A pre-meeting online questionnaire, comprising 20 objective questions about the treatment landscape and diagnosis of HCC in Saudi Arabia, was distributed to experts in the field of HCC management. An advisory board meeting including a panel of 13 experts was held in September 2022 where the responses to the survey questionnaire were reviewed and discussed. The survey results and experts' discussion highlighted the growing incidence of liver cancer in Saudi Arabia. HCC comprised the majority of all liver cancer cases due to rising rates of chronic viral infections and lifestyle-related risk factors. Most physicians in Saudi Arabia follow the Barcelona Clinic Liver Cancer guidelines as a prognostic tool for the detection and staging of patients with HCC. Most of the patients with HCC in Saudi Arabia are diagnosed in the intermediate or advanced stages with poor prognoses and limited therapeutic options. Establishing evidence-based surveillance techniques, a multidisciplinary approach to diagnosis, and better accessibility of treatment options is vital for the management of HCC in Saudi Arabia. Keywords: hepatocellular carcinoma, treatment patterns, multidisciplinary Hepatocellular carcinoma (HCC) is the sixth most common type of cancer and the third most common cause of cancer-related mortality in the world. 1,2 Risk factors for HCC vary according to geographic location and individual susceptibility. Major risk factors include chronic infection with hepatitis B (HBV) or hepatitis C (HCV) virus, and nonalcoholic fatty liver disease (NAFLD) which can be further categorized as nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) based on histopathological criteria. 3 While NAFL is generally nonprogressive and characterized by the presence of ≥5% hepatic steatosis without evidence of hepatocellular injury, NASH is characterized by the presence of >5% hepatic steatosis in conjunction with hepatocellular injury (such as hepatocyte ballooning) that often progresses to fibrosis, cirrhosis, and eventually HCC. 3 Other risk factors for HCC include alcoholic liver disease, consumption of aflatoxins, obesity associated with metabolic syndrome, type 2 diabetes (T2D), and smoking. 1,3,4 Temporal trends indicate a steady increase in the prevalence of liver cancer in the Arabian Gulf region with most cases reported from Saudi Arabia (83.4%) then Oman (6.6%), Kuwait (4.3%), Bahrain (2.4%), United Arab Emirates (1.8%), and Qatar (1.6%). 5,6 According to the most recent Saudi Cancer Registry 2018, liver cancer accounts for 3.1% of all newly diagnosed cancer cases ranking eighth among men and fourteenth among women. HCC comprises more than three-fourth of the liver cancer cases in Saudi Arabia with an age-standardized incidence rate (ASIR) of 5.2 per 100,000 people as compared with an ASIR of 4.7 per 100,000 people for the Western Asia region. 1,2,7–10 T -Abstract Truncated-
oncology